Drug Survival Of Biologic And Targeted Synthetic Disease-Modifying Antirheumatic Therapies In Patients With Inflammatory Arthritis: Data From Four Countries Of Latin America
22/05/2024
Exeni2, Nicolás Alvarado2, Graciela Gomez2, Alejandro Brigante2, David Vega Morales1, Iris Colunga Pedraza1, Sandra Sicsik Ayala1, Miguel Angel Saavedra Salinas1, Julio César Casasola Vargas1, Gabriela Ávila3, Sonia Cabrera3, Patricia Melgarejo3, Paola Pusineri3, Raquel Aranda3, Paola Jara4, Macarena Soto5, Cristina Bruego5, Darwin Cordovilla5, Belem Acevedo5, Sandra Consan5, Sofia Rostan5, Paloma de Abreu3 1Mexican College of Rheumatology, On behalf of Biobadamex Registry , Mexico City, Mexico, 2Argentine Society of Rheumatology, On behalf of Biobadasar Registry, CABA, Argentina, 3Paraguayan Society of Rheumatology, On behalf of Biobadaguay Registry, Asuncion, Paraguay, 4Paraguayan Society of Rheumatology, On behalf of Biobadaguay Registry, Asuncion, Argentina, 5Uruguayan Society of Rheumatology, On behalf of Biobadaguay Registry, Montevideo, Uruguay
Descargar documento